TH301 Emerges As a Novel Anti-Oncogenic Agent for Human Pancreatic Cancer Cells: The Dispensable Roles of P53, CRY2 and BMAL1 in TH301-Induced /p21 Upregulation

Overview

Journal Int J Mol Sci

Publisher MDPI

Date 2025 Jan 11

PMID 39796036

Authors

Danae Farmakis

Dimitrios J Stravopodis

Anastasia Prombona

Affiliations

Soon will be listed here.

Abstract

: Pancreatic Ductal Adeno-Carcinoma (PDAC) is a highly aggressive cancer, with limited treatment options. Disruption of the circadian clock, which regulates key cellular processes, has been implicated in PDAC initiation and progression. Hence, targeting circadian clock components may offer new therapeutic opportunities for the disease. This study investigates the cytopathic effects of TH301, a novel CRY2 stabilizer, on PDAC cells, aiming to evaluate its potential as a novel therapeutic agent. : PDAC cell lines (AsPC-1, BxPC-3 and PANC-1) were treated with TH301, and cell viability, cell cycle progression, apoptosis, autophagy, circadian gene, and protein expression profiles were analyzed, using MTT assay, flow cytometry, Western blotting, and RT-qPCR technologies. : TH301 proved to significantly decrease cell viability and to induce cell cycle arrest at the G1-phase across all PDAC cell lines herein examined, especially the AsPC-1 and BxPC-3 ones. It caused dose-dependent apoptosis and autophagy, and it synergized with Chloroquine and Oxaliplatin to enhance anti-oncogenicity. The remarkable induction of p21 by TH301 was shown to follow clock- and p53-independent patterns, thereby indicating the critical engagement of alternative mechanisms. : TH301 demonstrates significant anti-cancer activities in PDAC cells, thus serving as a promising new therapeutic agent, which can also synergize with approved treatment schemes by targeting pathways beyond circadian clock regulation. Altogether, TH301 likely opens new therapeutic windows for the successful management of pancreatic cancer in clinical practice.

References

Satoh T, Kaida D . Upregulation of p27 cyclin-dependent kinase inhibitor and a C-terminus truncated form of p27 contributes to G1 phase arrest. Sci Rep. 2016; 6:27829. PMC: 4901259. DOI: 10.1038/srep27829. View

Fu Z, Cheng X, Kuang J, Feng H, Chen L, Liang J . CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Mol Oncol. 2018; 12(4):529-544. PMC: 5891043. DOI: 10.1002/1878-0261.12179. View

Dong H, Qian D, Wang Y, Meng L, Chen D, Ji X . Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol. 2015; 13:189. PMC: 4469100. DOI: 10.1186/s12957-015-0605-7. View

Schwartz P, Nukaya M, Berres M, Rubinstein C, Wu G, Hogenesch J . The circadian clock is disrupted in pancreatic cancer. PLoS Genet. 2023; 19(6):e1010770. PMC: 10263320. DOI: 10.1371/journal.pgen.1010770. View

Roenneberg T, Merrow M . Circadian clocks - the fall and rise of physiology. Nat Rev Mol Cell Biol. 2005; 6(12):965-71. DOI: 10.1038/nrm1766. View

Shafi A, McNair C, McCann J, Alshalalfa M, Shostak A, Severson T . The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nat Commun. 2021; 12(1):401. PMC: 7810852. DOI: 10.1038/s41467-020-20513-5. View

Miller S, Son Y, Aikawa Y, Makino E, Nagai Y, Srivastava A . Isoform-selective regulation of mammalian cryptochromes. Nat Chem Biol. 2020; 16(6):676-685. DOI: 10.1038/s41589-020-0505-1. View

Gartel A, Tyner A . Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999; 246(2):280-9. DOI: 10.1006/excr.1998.4319. View

Dong Z, Zhang G, Qu M, Gimple R, Wu Q, Qiu Z . Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock. Cancer Discov. 2019; 9(11):1556-1573. PMC: 6983300. DOI: 10.1158/2159-8290.CD-19-0215. View

10.

Hoffman A, Zheng T, Ba Y, Stevens R, Yi C, Leaderer D . Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways. BMC Cancer. 2010; 10:110. PMC: 2860360. DOI: 10.1186/1471-2407-10-110. View

11.

Miki T, Matsumoto T, Zhao Z, Lee C . p53 regulates Period2 expression and the circadian clock. Nat Commun. 2013; 4:2444. PMC: 3798035. DOI: 10.1038/ncomms3444. View

12.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R . Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012; 31(1):23-9. DOI: 10.1200/JCO.2012.44.4869. View

13.

De Mei C, Ercolani L, Parodi C, Veronesi M, Lo Vecchio C, Bottegoni G . Dual inhibition of REV-ERBβ and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. Oncogene. 2014; 34(20):2597-608. PMC: 4761647. DOI: 10.1038/onc.2014.203. View

14.

Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad M . Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021; 12(1):4006. PMC: 8238982. DOI: 10.1038/s41467-021-24196-4. View

15.

Coqueret O, Gascan H . Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem. 2000; 275(25):18794-800. DOI: 10.1074/jbc.M001601200. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Pan M, Jiang C, Zhang Z, Achacoso N, Alexeeff S, Solorzano A . Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2023; 7:e2200570. DOI: 10.1200/PO.22.00570. View

18.

Chan A, Lamia K . Cancer, hear my battle CRY. J Pineal Res. 2020; 69(1):e12658. PMC: 7572572. DOI: 10.1111/jpi.12658. View

19.

Gurreri E, Genovese G, Perelli L, Agostini A, Piro G, Carbone C . KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Int J Mol Sci. 2023; 24(11). PMC: 10253344. DOI: 10.3390/ijms24119313. View

20.

Sulli G, Rommel A, Wang X, Kolar M, Puca F, Saghatelian A . Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018; 553(7688):351-355. PMC: 5924733. DOI: 10.1038/nature25170. View